Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Trinity Biotech (TRIB) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Trinity Biotech (TRIB) over the last 17 years, with Q2 2025 value amounting to $26.5 million.

  • Trinity Biotech's Accounts Payables rose 1478.72% to $26.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $26.5 million, marking a year-over-year increase of 1478.72%. This contributed to the annual value of $26.8 million for FY2024, which is 10920.17% up from last year.
  • According to the latest figures from Q2 2025, Trinity Biotech's Accounts Payables is $26.5 million, which was up 1478.72% from $26.8 million recorded in Q4 2024.
  • Over the past 5 years, Trinity Biotech's Accounts Payables peaked at $30.9 million during Q1 2021, and registered a low of $12.2 million during Q3 2023.
  • Moreover, its 5-year median value for Accounts Payables was $15.6 million (2022), whereas its average is $18.7 million.
  • As far as peak fluctuations go, Trinity Biotech's Accounts Payables tumbled by 4936.37% in 2022, and later surged by 10920.17% in 2024.
  • Quarter analysis of 5 years shows Trinity Biotech's Accounts Payables stood at $15.1 million in 2021, then increased by 1.64% to $15.4 million in 2022, then dropped by 16.73% to $12.8 million in 2023, then surged by 109.2% to $26.8 million in 2024, then fell by 1.11% to $26.5 million in 2025.
  • Its last three reported values are $26.5 million in Q2 2025, $26.8 million for Q4 2024, and $25.3 million during Q3 2024.